Načítá se...
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
BACKGROUND: Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new antidiabetic drug classes remains unclear. We therefore performed a network met...
Uloženo v:
| Vydáno v: | Cardiovasc Diabetol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6714383/ https://ncbi.nlm.nih.gov/pubmed/31462224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0916-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|